The North America Immune Repertoire Sequencing Market was valued at USD 326 million in 2025 and is projected to reach USD 1,024 million by 2035, growing at a CAGR of 11.2% from 2024 to 2035. This market is driven by the growing demand for advanced diagnostic solutions in oncology and immunology, increased prevalence of chronic diseases, and ongoing research and development investments by key industry players.
The economic impact of tariffs on "North America Immune Repertoire Sequencing Market".
Market Growth Drivers
Increasing Demand for Personalized Medicine: The demand for tailored therapeutic strategies in oncology, autoimmune, and infectious diseases is a significant driver for immune repertoire sequencing. Companies like Adaptive Biotechnologies are partnering with healthcare providers to leverage sequencing data to develop patient-specific treatments, increasing the adoption of such technologies across North America.
Expansion of Clinical and Translational Research: The adoption of sequencing technologies by research institutions and the growing number of publicly funded projects have contributed to the growth of this market. For instance, Illumina, in collaboration with research hospitals and universities, provides cutting-edge sequencing platforms that enable deeper insights into immune system profiling and disease mechanisms.
Market Trends
Integration with Artificial Intelligence and Big Data Analytics: Companies like Thermo Fisher Scientific are increasingly using AI and data analytics to manage and interpret the massive datasets generated from immune repertoire sequencing. These tools accelerate the discovery of disease biomarkers and facilitate the development of targeted therapies.
Rise of Single-cell Sequencing: The adoption of single-cell immune repertoire sequencing is on the rise, providing researchers with unprecedented insights into immune diversity at the cellular level. 10x Genomics, for example, has launched innovative single-cell platforms enabling high-resolution profiling, which is gaining traction among hospitals and research centers.
Market Opportunity
Expansion into Companion Diagnostics: With regulatory support for precision medicine, companies such as Adaptive Biotechnologies and Illumina are positioned to expand their immune repertoire sequencing solutions as companion diagnostics tools for targeted therapies, unlocking new revenue streams and enhancing treatment outcomes.
Growing Adoption in Infectious Disease Diagnostics: The increasing usage of immune repertoire sequencing to monitor immune responses to emerging infectious threats, such as COVID-19 and other viral pathogens, presents substantial growth opportunities for market participants.
North America Immune Repertoire Sequencing Market Revenue (USD Million), 2020-2035
The revenue chart for the North America Immune Repertoire Sequencing Market demonstrates consistent growth from 2020 to 2035, driven by advancements in sequencing technologies, rising investments in healthcare R&D, and greater application in personalized medicine. Market revenue is estimated to increase from USD 120 million in 2020, reaching USD 326 million in 2025, and projected to further grow to USD 1,024 million by 2035 with a CAGR of 11.2%. This uptrend reflects widespread adoption among clinical research, academic, and healthcare institutions across the region.
North America Immune Repertoire Sequencing Market by Region (% Share), 2025
The 2025 market share analysis highlights the dominance of the United States, accounting for 73% of the regional market. Canada follows with a 16% share, showing significant adoption due to research funding and healthcare initiatives. Mexico holds a 7% share, while Rest of North America—including territories such as Bermuda and the Caribbean—represents 4%. The prominence of the U.S. is due to high R&D investments, advanced healthcare infrastructure, and broad uptake among biopharma and diagnostics companies.
Recent Developments
In March 2024, Adaptive Biotechnologies announced the launch of its new immunoSEQ T-MAP COVID platform, providing high-throughput immune profiling solutions to analyze patients’ immune responses post-infection or vaccination. This innovation targets expanding clinical utility to infectious disease monitoring and public health response.
In February 2024, Illumina and the Dana-Farber Cancer Institute announced a partnership to integrate immune repertoire sequencing into cancer immunotherapy clinical trials. The collaboration aims to leverage Illumina NGS technologies for improved biomarker discovery and personalized immuno-oncology solutions, accelerating the clinical adoption in North America.
In January 2024, 10x Genomics introduced Chromium X, an upgraded single-cell immune profiling platform targeted at academic and pharmaceutical research markets. The new system enables broader scalability and deeper insights into immune cell diversity, further propelling the adoption of single-cell immune repertoire sequencing in the region.
Press Releases